Page 8 - Downstream Processing News Today

/PRNewswire/ -- A new market study published by Global Industry Analysts Inc., (GIA) the premier market research company, today released its report titled...

/PRNewswire/ -- A new market study published by Global Industry Analysts Inc., (GIA) the premier market research company, today released its report titled...

Moderna will build a state-of-the-art mRNA facility in Africa, with the goal of producing up to 500 million vaccine doses a year.

We track some of the more recent developments in biopharma manufacturing tech.

RheaVita, a company developing continuous freeze-drying technology for biopharma products, has closed a €2.5m (US$3.04m) Series A financing round.

Downstream Processing Market – Scope of the Report This report on the global downstream processing market studies the past as well as current growth trends and opportunities to gain valuable insights of these indicators for the global market during the forecast period from 2020 to 2030.New York, June 02, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Downstream Processing Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 202...

Samsung Biologics to provide fill-finish manufacturing for Moderna’s COVID-19 vaccine Samsung Biologics will provide large-scale fill-finish manufacturing for Moderna’s COVID-19 vaccine from its facilities in South Korea. Upon execution of the deal, technology transfer will commence immediately. Samsung Biologics’ Incheon facilities will use a state-of-the-art production line equipped for aseptic fill-finish, labeling, and packaging services. The agreement will...

New BD plant set for Spain aims to meet growing demand for PFS Becton, Dickinson and Company (BD) is to build a new plant in Zaragoza, Spain, with an investment of €165m (US$200m). The site will produce glass pre-filled syringes and plastic components. “BDs new plant in Zaragoza will produce drug delivery devices, primarily for pharmaceutical companies that supply the European market with drugs in PFS such as vaccines and other biologics,”​ said Eric Borin, w...

Ontario-based, Nicoya Lifesciences, is in the process of completing a prototype of a low-cost, single-use device that tests for active SARS-CoV-2 infection, variants and, eventually, other viruses. The novel test is called Atlas. Users administer the Atlas test themselves with a simple saliva collection kit. After that, a smartphone application provides results, in only 20 minutes – without complex lab equipment or highly trained technicians.  Atlas was develop...

The two companies first initiated collaboration back in February 2018. Michael S Weiss, CEO of TG Therapeutics, a firm focused on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases, said the partnership with Samsung will ensure stable supply of ublituximab as it looks to the potential commercialization of the drug. “With the recent positive ULTIMATE I and II MS Phase 3 studies, we re-evaluated our supply needs and were very ...